FDA 483 - McPherson Enterprises, Inc., dba Implantable Devices - September 06, 2023

During an inspection conducted on September 5-6, 2023, McPherson Enterprises, Inc., operating as Implantable Devices, received an FDA Form 483 detailing four significant observations related to its manufacturing processes for medical devices, specifically carotid shunts.

The Food and Drug Administration identified critical deficiencies in the company's quality system. Observation 1 noted that acceptance criteria were not established for validation activities, particularly for the shelf life study of carotid shunts, failing to assure sterility and device conformity. This was a repeat observation. Observation 2 highlighted inadequate risk analysis within the Design FMEA for carotid shunt devices, failing to adequately identify and mitigate potential failure causes, also a repeat finding.

Further issues included Observation 3, where the firm failed to adequately establish procedures for evaluating suppliers and contract sterilizers to ensure product and service conformity, a repeat observation from the previous inspection. Lastly, Observation 4 indicated a lack of established procedures for controlling environmental conditions, such as temperature and humidity, during the storage of finished carotid shunt devices, another repeated concern.

These observations indicate non-compliance with quality system requirements for medical device manufacturers under FDA regulations. McPherson Enterprises, Inc. is responsible for conducting internal self-audits, addressing these findings, and implementing appropriate corrective and preventive actions to ensure the safety and effectiveness of its products.